Abstract
In this study, gene expression profiling was performed on 103 neuroblastoma (NB) tumors, stages 1–4 with and without MYCN amplification, using cDNA microarrays containing 42 578 elements. Using principal component analysis (PCA) to analyse the relationships among these samples, we confirm that the global patterns of gene expression reflect the phenotype of the tumors. To explore the biological processes that may contribute to increasing aggressive phenotype of the tumors, we utilized a statistical approach based on PCA. We identified a specific subset of the cell cycle and/or chromosome segregation genes that distinguish stage 4 NB tumors from all lower stage tumors, including stage 3. Furthermore, the control of the kinetochore assembly emerges from the Gene Ontology analysis as one of the key biological processes associated with an aggressive NB phenotype. Finally, we establish that these genes are further upregulated in the most aggressive MYCN-amplified tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- NB:
-
neuroblastoma
- ST1:
-
stage 1
- ST2:
-
stage 2
- ST3:
-
stage 3
- NBMYCN-AMP:
-
MYCN amplified
- NBMYCN-NA:
-
MYCN not amplified
- PCA:
-
principal component analysis
- GO:
-
gene ontology
References
Alaminos M, Mora J, Cheung NK, Smith A, Qin J, Chen L and Gerald WL . (2003). Cancer Res., 63, 4538–4546.
Alter O, Brown PO and Botstein D . (2000). Proc. Natl. Acad. Sci. USA, 97, 10101–10106.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM and Sherlock G . (2000). Nat. Genet., 25, 25–29.
Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schafer H, Christiansen H and Eilers M . (2002). Cancer Cell, 2, 377–386.
Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M and Versteeg R . (2001). EMBO J., 20, 1383–1393.
Brodeur GM . (2003). Nat. Rev. Cancer, 3, 203–216.
Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS and Trent JM . (2002). Bioinformatics, 18, 1207–1215.
Cohn SL, Rademaker AW, Salwen HR, Franklin WA, Gonzales-Crussi F, Rosen ST and Bauer KD . (1990). Am. J. Pathol., 136, 1043–1052.
Dominici C, Negroni A, Romeo A, McDowell H, Padula A, Pucci S, Cappelli C, Castello MA and Raschella G . (1992). Anticancer Res., 12, 59–63.
Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S and Balmain A . (2003). Nat. Genet., 34, 403–412.
Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A and Amati B . (2003). Genes Dev., 17, 1115–1129.
Hegde P, Qi R, Abernathy K, Gay C, Dharap S, Gaspard R, Hughes JE, Snesrud E, Lee N and Quackenbush J . (2000). Biotechniques, 29, 548–550, 552–554, 556 passim.
Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y and Nakagawara A . (2000). Oncogene, 19, 617–623.
Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C and Meltzer PS . (2001). Nat. Med., 7, 673–679.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC . (1998). Nature, 396, 580–584.
McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, Breatnach F, Catchpoole D, Culhane AC, Jeffery I, Gallagher WM and Stallings RL . (2004). Carcinogenesis, 9, 1599–1609.
Mora J, Gerald WL and Cheung NK . (2003). Cancer Lett., 197, 119–124.
Negroni A, Scarpa S, Romeo A, Ferrari S, Modesti A and Raschella G . (1991). Cell Growth Differ., 2, 511–518.
Ruggero D and Pandolfi PP . (2003). Nat. Rev. Cancer, 3, 179–192.
Schmidt ML, Salwen HR, Manohar CF, Ikegaki N and Cohn SL . (1994). Cell Growth Differ., 5, 171–178.
Schwab M, Westermann F, Hero B and Berthold F . (2003). Lancet Oncol., 4, 472–480.
Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R and Schwab M . (1990). Cancer Res., 50, 4411–4416.
Sugihara E, Kanai M, Matsui A, Onodera M, Schwab M and Miwa M . (2004). Oncogene, 23, 1005–1009.
Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y and Aburatani H . (2004). Genes Chromosomes Cancer, 40, 120–132.
Tonini GP and Romani M . (2003). Cancer Lett., 197, 69–73.
van Noesel MM and Versteeg R . (2004). Gene, 325, 1–15.
Wang E, Miller LD, Ohnmacht GA, Liu ET and Marincola FM . (2000). Nat. Biotechnol., 18, 457–459.
Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M and Khan J . (2004). Cancer Res., 64, 6883–6891.
Wei JS and Khan J . (2002). DNA Microarrays: A Molecular Cloning Manual Bowtell D and SJ (eds). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, pp. 110–119.
Westermann F and Schwab M . (2002). Cancer Lett., 184, 127–147.
Zar JH . (1999). Biostatistical Analysis. Prentice-Hall: Upper Saddle River, NJ.
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S . (1998). Nat. Genet., 20, 189–193.
Acknowledgements
We thank Dr John Maris, and Children's Oncology Group (COG) and Dr Steven Qualman at the Cooperative Human Tissue Network for several of the tumors.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary information accompanies the paper on Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Krasnoselsky, A., Whiteford, C., Wei, J. et al. Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene 24, 1533–1541 (2005). https://doi.org/10.1038/sj.onc.1208341
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208341
Keywords
This article is cited by
-
Role of the CASZ1 transcription factor in tissue development and disease
European Journal of Medical Research (2023)
-
KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma
Nature Communications (2021)
-
CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo
BMC Cancer (2019)
-
HOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptome
BMC Genomics (2014)
-
Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status
BMC Medical Genomics (2011)